M&A / Deals Daiichi Sankyo and Interna partner for MNM-targeted delivery solutions Pharmaceutical TechnologyDaiichi Sankyo has partnered with Interna Therapeutics to develop targeted delivery solutions based on molecular nano motor (MNM) technology.M&A / DealsRead full story pharminent April 17, 2026 (Last updated: April 17, 2026) Pharmaceutical Technology Daiichi Sankyo has partnered with Interna Therapeutics to develop targeted delivery solutions based on molecular nano motor (MNM) technology. M&A / DealsRead full story Post navigation Previous: Erica Schwartz, ex-deputy surgeon general, picked to be next CDC directorNext: Trump names Erica Schwartz to fill leadership void at CDC Related Stories M&A / Deals Solstice Oncology secures $225m to drive porustobart’s development for cancer pharminent September 10, 2026 M&A / Deals UK’s Claret Capital raises 575m for European biotechs pharminent September 7, 2026 M&A / Deals GSK wagers up to $1.3B on a different kind of cancer drug pharminent September 3, 2026